Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci

Clinical Cancer Research

Volumn 11, Issue 11, 2005, Pages 4097-4106

  Bastian, Patrick J ^a   Ellinger, Jörg ^a   Wellmann, Axel ^a   Wernert, Nicolas ^a   Heukamp, Lukas C ^a   Müller, Stefan C ^a   Von Ruecker, Alexander ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; APC GENE; ARTICLE; CANCER DIAGNOSIS; CPG ISLAND; DIAGNOSTIC ACCURACY; GENE; GENE LOCUS; GSTP1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MDR1 GENE; METASTASIS; METHYLATION; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PTGS1 GENE; PTGS2 GENE; RASSF1A GENE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADENOMATOUS POLYPOSIS COLI PROTEIN; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CPG ISLANDS; CYCLOOXYGENASE 2; DNA METHYLATION; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; P-GLYCOPROTEIN; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTATE; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEINS;

EID: 20344374987     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1832     Document Type: Article

References (54)

1. Lerner SE, Seay TM, Blute ML, et al. Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis. J Urol 1996;155:821-6.
2. Soh S, Kattan MW, Berkman S, Wheeler TM, Scardino PT. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol 1997;157:2212-8.
3. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439-43.
4. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
5. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
6. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
7. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globoscan 200. Int J Cancer 2001;94:153-5.
8. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81.
9. de la Taille A, Antiphon P, Salomon L, et al. Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology 2003;61:1181-6.
10. Makhlouf AA, Krupski TL, Kunkle D, Theodorescu D. The effect of sampling more cores on the predictive accuracy of pathological grade and tumour distribution in the prostate biopsy. BJU Int 2004;93:271-4.
11. De Marzo AM, Meeker AK, Zha S, et al. Human prostate cancer precursors and pathobiology. Urology 2003;62:55-62.
12. Jiang Z, Iczkowski KA, Woda BA, Tretiakova M, Yang XJ. P504S immunostaining boosts diagnostic resolution of "suspicious" foci in prostatic needle biopsy specimens. Am J Clin Pathol 2004;121:99-107.
13. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB. Decreased gene expression of steroid 5 α-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 2003;57:134-9.
14. Parsons JK, Gage WR, Nelson WG, De Marzo AM. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology 2001;58:619-24.
15. Signoretti S, Waltregny D, Ditks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1769-75.
16. Zhou M, Aydin H, Kanane H, Epstein JI. How often does α-methylacyl-CoA-racemase contribute to resolving an atypical diagnosis on prostate needle biopsy beyond that provided by basal cell markers? Am J Surg Pathol 2004;8:239-43.
17. DeMarzo AM, Nelson WG, Isaacs WE, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361:955-64.
18. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004;10:3943-53.
19. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
20. Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the π-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91:11733-7.
21. Goessl C, Muller M, Miller K. Methylation-specific PCR (MSP) for detection of tumour DNA in the blood plasma and serum of patients with prostate cancer. Prostate Cancer Prostatic Dis 2000;3:S17.
22. Nakayama M, Gonzalgo ML, Yegnasubramanian S, et al. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 2004;91:459-77.
23. Esteller M, Corn PG, Baylin SB, Herman JG, A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9.
24. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002;8:514-9.
25. Yamanaka M, Watanabe M, Yamada Y, et al. Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer 2003;106:382-7.
26. Kang GH, Lee S, Lee HJ, Hwang KS. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004;202:233-40,
27. Nagase H, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat 1993;2:425-34.
28. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975-86.
29. Li LC, Zhao H, Shiina H, Kane CJ, Dahiya R. PGDB: a curated and integrated database of genes related to prostate cancer. Nucleic Acids Res 2003;31:291-3.
30. Zha S, Gage WR, Sauvageot J, et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001;61;8617-23.
31. Kantharidis P, El-Osta A, de Silva M, et al. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance. Clin Cancer Res 1997;3:2025-32.
32. Mahadovan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 2004;104:1940-51.
33. Nagase H, Nakamura Y. Mutations of the PAC (adenomatous polyposis coli) gene. Hum Mutat 1993;2:425-34.
34. Siegsmund MJ, Kreukler C, Steidler A, et al. Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein. Urol Res 1997;25:35-41.
35. Tada Y, Wada M, Kuroiwa K, et al. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res 2000;6:4618-27.
36. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1a in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-9.
37. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from lung tumor suppressor locus 3p21.3. Nat Genet 2000;25:315-9.
38. Dammann R, Schagdarsurengin U, Liu L, et al. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 2003;22:3806-12.
39. Dammann R, Schagdarsurengin U, Strunnikova M, et al. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol 2003;18:665-77.
40. Florl AR, Steinhoff C, Müller M, et al. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 2004;91:985-94.
41. Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 2002;21:6835-40.
42. Song MS, Song SJ, Ayad NG, et al. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 2004;6:129-37.
43. Woodson K, Hanson J, Tangrea J. A survey of gene-specific methylation in human prostate cancer among black and white men. Cancer Lett 2004;205:181-8.
44. Grunau C, Clark SJ, Rosenthal A. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res 2001;29: E65-70.
45. Eads CA, Lord RV, Wickramasinghe K, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61:3410-8.
46. Lehmann U, Langer F, Feist H, et al. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002;160:605-12.
47. Li R, Younes M, Frolov A, et al. Expression of neutral amino acid transporter ASCT2 in human prostate. Anticancer Res 2003;23:3413-8.
48. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71.
49. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51.
50. Jeronimo C, Usadel H, Henrique R, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 2002;60:1131-5.
51. Kawai K, Sakurai M, Sakai T, et al. Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies. Cancer Lett 2000;150:147-53.
52. Tokumaru Y, Harden SV, Sun DI, et al. Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 2004;10:5518-22.
53. Woodson K, Gillespie J, Hanson J, et al. Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: a histopathologic study of whole mount prostate specimens. Prostate 2004;60:25-31.
54. Enokida H, Shiina H, Igawa M, et al. CpG Hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res 2004;64:5956-62.